Pilot of UPLYFT with Lymphoma Survivors for Lymphoma

Phase-Based Progress Estimates
Dana-Farber Cancer Institute, Boston, MALymphoma+1 MorePilot of UPLYFT with Lymphoma Survivors - Behavioral
All Sexes
What conditions do you have?

Study Summary

This trial is testing an intervention to help improve quality of life and reduce lymphoma-related worries for survivors.

Eligible Conditions
  • Lymphoma
  • Survivorship

Treatment Effectiveness

Study Objectives

3 Primary · 7 Secondary · Reporting Duration: Up to 6 months

Up to 6 months
Acceptability: Disenrollment Rate
Acceptability: Satisfaction Rate
Feasibility: Data Collection Completion Rate
Feasibility: Enrollment Rate
Feasibility: Program Session Completion Rate
Preliminary efficacy: Anxiety Change
Preliminary efficacy: Depression Change
Preliminary efficacy: Fear of Cancer Recurrence (FCR) Change
Preliminary efficacy: Psychological inflexibility Change
Preliminary efficacy: Quality of Life Change

Trial Safety

Trial Design

3 Treatment Groups

Clinicians Interviews
1 of 3
1 of 3
Lymphoma Survivors Field Test
1 of 3

Experimental Treatment

74 Total Participants · 3 Treatment Groups

Primary Treatment: Pilot of UPLYFT with Lymphoma Survivors · No Placebo Group · N/A

Clinicians Interviews
Experimental Group · 1 Intervention: Interview with Clinicians · Intervention Types: Other
Experimental Group · 1 Intervention: Pilot of UPLYFT with Lymphoma Survivors · Intervention Types: Behavioral
Lymphoma Survivors Field Test
Experimental Group · 1 Intervention: Field Test of UPLYFT with Lymphoma Survivors · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 6 months

Who is running the clinical trial?

American Society of HematologyOTHER
8 Previous Clinical Trials
20,407 Total Patients Enrolled
Dana-Farber Cancer InstituteLead Sponsor
1,026 Previous Clinical Trials
753,902 Total Patients Enrolled
59 Trials studying Lymphoma
2,385 Patients Enrolled for Lymphoma
Oreofe O Odejide, MD, PhDPrincipal InvestigatorOreofe_Odejide@dfci.harvard.edu

Eligibility Criteria

Age 18+ · All Participants · 12 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are pregnant.
You must be under the care of an oncologist for your lymphoma or a mental health clinician for your cancer.

Frequently Asked Questions

How many participants are partaking in this experiment?

"Affirmative. According to clinicaltrials.gov, this experiment is actively recruiting patients with a posted date of February 8th 2022 and an amended posting on March 14th 2022. The study seeks 74 participants at one medical centre." - Anonymous Online Contributor

Unverified Answer

What is the ultimate intent of this clinical inquiry?

"This clinical trial will assess the feasibility of program session completion rate over a 6 month period. Secondary parameters such as pre-intervention to post-intervention changes in anxiety (as measured by Hospital and Anxiety Scale) and psychological inflexibility (as assessed via Acceptance and Action Questionnaire-II) are also being evaluated, with an acceptability threshold set at ≤ 10% disenrollment rate." - Anonymous Online Contributor

Unverified Answer

Is enrollment currently open for this research study?

"This trial, which was initially listed on February 8th 2022, is still open for patient recruitment. Accordingly, it has been updated as recently as March 14th 2022." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.